Home

Download

Statistics

Landscape

Help

Contact

	Dataset summary
	Drug summary
	Umap of single cell types and conditions (resistant and sensitive)
	Comparison of cell composition between the resistant and sensitive groups (This dataset does not contain this module)
	Comparison of intra-tumor heterogeneity (ITH) and epithelial-mesenchymal transition (EMT) scores of malignant cells between the resistant and sensitive groups
	Difference of cell-cell interactions between the resistant and sensitive groups
	Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type
	Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples (This dataset does not contain this module)
	Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines
	MicroRNAs (miRNAs) regulating drug resistance-related DEGs for Malignant cells
	Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type
•	Differentially expressed genes act as transcription factors

Dataset: GSE153697

Dataset summary for GSE153697

Datast information	Dataset	GSE153697
	PMID	33558546
	Raw data ID/link	PRJNA643723
	Organism	Homo sapiens
	Source	patients
	Tissue	Bone marrow aspirate
	Cancer type level1	Acute lymphoblastic leukemia
	Cancer type level2	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)
	Regimen	anti-CD19 CAR-T
	Drug type	Immunotherapy
	Sample size	resistant 1, sensitive 1
	Cell number	2919
	Extract protocol	10x genomics
	Data processing	CellRanger 3.0.1
	Public date	Public on Dec 11, 2020
	Description	This dataset has 1 patient with a sensitive pre-treatment sample and a resistant post-treatment sample.

Top

Drug summary for GSE153697

Drug name	DrugBank ID	Drug type	Targets name	Targets uniprot ID
"anti-CD19 CAR-T" is not included in the drug list.

Top

Umap of single cell types and conditions (resistant and sensitive)

Umap of cell types and conditions (resistant and sensitive). If this dataset has both pre-treatment and post-treatment samples, the cell types were annotated together. If this dataset is a cell line dataset, the UMAP of cell clusters and the cell ratio of drug-resistant and sensitive groups within each cluster will also be shown. (If the image exists, the user can click on it to enlarge it in a new window.)

Umap of cell types

Umap of conditions

Top

Comparison of cell composition between the resistant and sensitive groups

In the pre-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

In the post-treatment samples, the cell composition of the resistant and sensitive groups were compared.
* represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Comparison of ITH and EMT scores of malignant cells between the resistant and sensitive groups

Comparison of ITH (intra-tumoral heterogeneity) and EMT (epithelial-mesenchymal transition) scores of malignant cells between the resistant and sensitive groups. ITH represents intratumoral heterogeneity, EMT represents epithelial mesenchymal transition, pre represents pre-treatment, post represents post-treatment, post2 represents longer post-treatment. (If the image exists, the user can click on it to enlarge it in a new window.)

Comparison of ITH scores

Comparison of EMT scores

Top

Difference of cell-cell interactions between the resistant and sensitive groups

In the pre-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

In the post-treatment samples, the difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The difference in cell-cell interactions between the resistant and sensitive groups was compared. The numbers indicate the count of cell-cell interactions that were either higher or lower in the resistant group compared to the sensitive group. The dot plots of significant ligand-receptor pairs in the resistant group and sensitive group are subsequently displayed. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

resistant vs. sensitive

Dot plot of significant ligand-receptor pairs in the resistant group	Dot plot of significant ligand-receptor pairs in the sensitive group

Top

Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type

In the pre-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

In the post-treatment samples, the differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The following are differentially expressed genes (|avg_log2FC|>0.25 & p_val_adj<0.05) between the resistant and sensitive groups for each cell type.

Gene symbol	Gene id	avg_log2FC	p_val	p_val_adj	pct.1	pct.2	Cell type	Timepoint
DCAF13	ENSG00000164934	0.375891	6.07e-33	9.74e-29	0.535	0.271	Malignant cells	NA
UBL5	ENSG00000198258	0.373903	4.71e-33	7.55e-29	0.956	0.846	Malignant cells	NA
MTCH2	ENSG00000285121	0.372797	1.76e-30	2.82e-26	0.541	0.288	Malignant cells	NA
ATP5MPL	NA	0.372687	3.47e-32	5.56e-28	0.928	0.769	Malignant cells	NA
SNU13	ENSG00000100138	0.372457	9.85e-29	1.58e-24	0.885	0.723	Malignant cells	NA
FBL	ENSG00000280548	0.372278	5.85e-24	9.39e-20	0.811	0.628	Malignant cells	NA
MARCH7	NA	0.372195	1.04e-28	1.66e-24	0.485	0.245	Malignant cells	NA
LSM10	ENSG00000181817	0.371936	3.31e-39	5.31e-35	0.435	0.164	Malignant cells	NA
AASDHPPT	ENSG00000149313	0.371376	2.67e-38	4.29e-34	0.48	0.2	Malignant cells	NA
SERINC3	ENSG00000132824	0.371283	2.03e-24	3.25e-20	0.572	0.354	Malignant cells	NA
AKR1B1	ENSG00000085662	0.371227	4.36e-25	6.99e-21	0.627	0.4	Malignant cells	NA
CISD1	ENSG00000122873	0.369428	0.00e+00	2.80e-45	0.359	0.085	Malignant cells	NA
CAPRIN1	ENSG00000135387	0.36883	2.94e-21	4.72e-17	0.715	0.517	Malignant cells	NA
DCAF7	ENSG00000136485	0.368525	7.45e-28	1.20e-23	0.694	0.445	Malignant cells	NA
AKR1A1	ENSG00000117448	0.368193	1.51e-22	2.41e-18	0.807	0.659	Malignant cells	NA
UBASH3B	ENSG00000154127	0.36747	3.61e-23	5.79e-19	0.53	0.308	Malignant cells	NA
ICAM2	ENSG00000108622	0.367095	1.05e-25	1.68e-21	0.434	0.219	Malignant cells	NA
ZNF22	ENSG00000165512	0.36681	2.26e-26	3.63e-22	0.773	0.551	Malignant cells	NA
METTL5	ENSG00000138382	0.366731	3.29e-34	5.28e-30	0.555	0.275	Malignant cells	NA
VTA1	ENSG00000009844	0.366442	3.90e-38	6.26e-34	0.455	0.179	Malignant cells	NA
NOP56	ENSG00000101361	0.366176	2.28e-20	3.66e-16	0.614	0.425	Malignant cells	NA
SF3B4	ENSG00000143368	0.36565	4.37e-28	7.01e-24	0.661	0.417	Malignant cells	NA
POLR2H	ENSG00000163882	0.365576	6.06e-36	9.72e-32	0.406	0.153	Malignant cells	NA
IDH2	ENSG00000182054	0.365517	2.37e-20	3.81e-16	0.73	0.57	Malignant cells	NA
SRSF1	ENSG00000136450	0.364607	1.42e-25	2.28e-21	0.686	0.457	Malignant cells	NA
ETFA	ENSG00000140374	0.364107	9.82e-30	1.57e-25	0.68	0.419	Malignant cells	NA
TMEM69	ENSG00000159596	0.363527	1.18e-30	1.90e-26	0.414	0.184	Malignant cells	NA
NUCB2	ENSG00000070081	0.363138	1.72e-19	2.76e-15	0.755	0.585	Malignant cells	NA
MRPL43	ENSG00000055950	0.362959	1.85e-31	2.97e-27	0.548	0.28	Malignant cells	NA
ESD	ENSG00000139684	0.362926	6.81e-29	1.09e-24	0.745	0.495	Malignant cells	NA
VNN2	ENSG00000112303	0.362114	4.11e-30	6.59e-26	0.292	0.092	Malignant cells	NA
CLTA	ENSG00000122705	0.361891	8.56e-37	1.37e-32	0.477	0.203	Malignant cells	NA
GBP4	ENSG00000162654	0.361647	2.87e-19	4.60e-15	0.63	0.446	Malignant cells	NA
CTPS1	ENSG00000171793	0.360915	9.03e-28	1.45e-23	0.558	0.31	Malignant cells	NA
NDUFC1	ENSG00000109390	0.360896	1.70e-29	2.73e-25	0.507	0.259	Malignant cells	NA
SPN	ENSG00000197471	0.36041	8.08e-26	1.30e-21	0.504	0.275	Malignant cells	NA
NDUFS3	ENSG00000285387	0.360076	8.97e-26	1.44e-21	0.676	0.454	Malignant cells	NA
UTP11	ENSG00000183520	0.35994	3.18e-33	5.10e-29	0.442	0.191	Malignant cells	NA
FAM216A	ENSG00000204856	0.359113	6.90e-38	1.11e-33	0.407	0.145	Malignant cells	NA
CKS2	ENSG00000123975	0.358474	1.62e-26	2.60e-22	0.534	0.294	Malignant cells	NA
TCP1	ENSG00000120438	0.358318	2.00e-22	3.21e-18	0.775	0.582	Malignant cells	NA
MCM2	ENSG00000073111	0.357953	3.99e-30	6.40e-26	0.366	0.141	Malignant cells	NA
STAG2	ENSG00000101972	0.357856	5.19e-23	8.32e-19	0.762	0.57	Malignant cells	NA
LAPTM4A	ENSG00000068697	0.357461	3.01e-27	4.83e-23	0.779	0.556	Malignant cells	NA
SDAD1	ENSG00000198301	0.356474	4.06e-29	6.52e-25	0.489	0.246	Malignant cells	NA
CCT7	ENSG00000135624	0.35618	5.91e-21	9.49e-17	0.731	0.541	Malignant cells	NA
TMED9	ENSG00000184840	0.355734	2.03e-23	3.26e-19	0.765	0.581	Malignant cells	NA
RAD51C	ENSG00000108384	0.354319	1.34e-37	2.15e-33	0.375	0.126	Malignant cells	NA
CEBPZ	ENSG00000115816	0.354207	2.40e-26	3.85e-22	0.561	0.322	Malignant cells	NA
SSRP1	ENSG00000149136	0.354051	1.04e-20	1.67e-16	0.659	0.463	Malignant cells	NA

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples

Enrichment results for 5 known drug-resistant mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of pre-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window.Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples

Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group of post-treatment samples. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Top

Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Enrichment results for 5 known drug resistance mechanisms in malignant cells and 1 known mechanism in TME cells are shown here.The "Signature" column represents the differentially expressed genes (DEGs) used for enrichment. The "Geneset" column represents the genes included in this mechanism. The "Overlap" column represents the number of genes in the "Geneset" that are enriched in the "Signature". The "Enriched Genes" column represents the genes in the "Geneset" that are enriched in the "Signature". (If the image exists, the user can click on it to enlarge it in a new window.)

Enrichment results for 5 known drug resistance mechanisms in malignant cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Unusual Activation of Pro-survival Pathway	5.80e-14	2.90e-13	1239	781	94	23467	Malignant cells	ANXA2,AREG,BCL11A,CCND2,CDK4,CDKN1A,CDKN1B,CERS2,CIAPIN1,CTNNB1,DNMT1,GAS7,GSTP1,SLC2A1,HIF1A,HMGA1,HMGB1,IDH2,JUN,PKM,MCL1,MAP1LC3B,MYC,PARP1,RHOA,S100A4,STMN1,TP53INP1,YWHAZ,SLC25A5,GRK2,BID,BNIP2,BTG1,CD44,HSPD1,CHEK1,CLTC,DCK,DNMT3A,DUSP1,DHFR,ENG,EIF3A,HSP90B1,EZR,GAPDH,NR3C1,HAX1,HMGB2,HSPA8,HSPB1,IKZF1,KDM5B,KEAP1,LDHA,LRRFIP1,MDM4,MSH2,MSH6,MYD88,NUCKS1,PABPC1,PGK1,PIK3CD,PRKDC,PSMB5,RAP1B,RRM1,HNRNPA1,SDHB,SFPQ,SMC4,SOD2,SRSF2,TPT1,TFAM,TOP1,TOP2B,TRIM27,UCP2,YEATS4,ZKSCAN1,ENO1,GNAS,CALR,SMARCA4,NPM1,EIF4EBP1,REL,BRD2,OGT,G3BP1,HSH2D
Aberration of the Drug's Therapeutic Target	1.00e-01	2.10e-01	1239	90	8	23467	Malignant cells	CDK4,IDH2,DHFR,MSH6,CD19,SF3B1,NPM1,AKR1B1
Irregularity in Drug Uptake and Drug Efflux	1.30e-01	2.10e-01	1239	37	4	23467	Malignant cells	SLC2A1,ABCE1,TAP1,SLC29A1
Drug Inactivation by Structure Modification	1.70e-01	2.10e-01	1239	27	3	23467	Malignant cells	GSTP1,DCK,SOD2
Epigenetic Alteration of DNA, RNA or Protein	1.00e+00	1.00e+00	1239	455	13	23467	Malignant cells	DNMT1,H2AFY,IDH2,EIF4G2,LMNA,PMAIP1,ARID4B,DNMT3A,GAPDH,SMC4,MALAT1,PPP1R15A,MT-CO2

Enrichment results for 1 known drug resistance mechanisms in TME cells

Mechnism	Pval	FDR	Signature	Geneset	Overlap	Background	Cell type	Enriched Genes
Regulation by the Disease Microenvironment	2.40e-02	2.40e-02	30	186	2	23467	Mono_Macro	ZEB2,CXCR4
Regulation by the Disease Microenvironment	1.00e+00	1.00e+00	62	186	0	23467	Physiology B cells	NA

Hallmark, KEGG and GOBP enrichment results for up-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Up-regulated Hallmark	Up-regulated KEGG	Up-regulated GO BP

Hallmark, KEGG and GOBP enrichment results for down-regulated genes in resistant group. Only show the top 50 pathways with fdr<0.05. If certain cell types are not displayed, it means that there are no significant pathways based on DEGs in those cell types. (If the image exists, the user can click on it to enlarge it in a new window. Complete files can be downloaded from the download section.)

Down-regulated Hallmark	Down-regulated KEGG	Down-regulated GO BP

Top

MicroRNAs (miRNAs) regulating drug resistance-related DEGs for malignant cells

In the pre-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

In the post-treatment samples, the miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. If the gene does not have any miRNAs with a score greater than 80, it will not be shown. Here only the names of miRNAs with a score greater than 90 are shown, but some names will not be shown because of too many overlaps. (Complete files containing all datasets and cell types can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. The miRNAs with a score greater than 80 that regulate the top10 abs(avg_log2FC) drug resistance-related DEGs for Malignant cells are shown here. Here only the names of miRNAs with a score greater than 80 are shown, but some names will not be shown because of too many overlaps. If the gene does not have any miRNAs with a score greater than 90, it will not be shown. (Complete files containing all datasets and cell types can be downloaded from the download section.)

Regulating up-regulated DEGs in resistant group	Regulating down-regulated DEGs in resistant group

Top

Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type

In the pre-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

In the post-treatment samples, the motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

This dataset only has one patient or is a cell line dataset, the resistant sample is the post-treatment sample and the sensitive sample is the pre-treatment sample. Motifs and TFs that regulate drug resistance-related DEGs for each cell type are shown here. (Complete files can be downloaded from the download section.)

Motifs and TFs regulating up-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	jaspar__MA1483.2	5.91	0.0584	ELF2 (directAnnotation).	Malignant cells
	metacluster_191.2	5.76	0.0575	ELK4; NR2C2; NR2C2; NR2C2; NR2C2 (directAnnotation). GABPA (inferredBy_Orthology).	Malignant cells
	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	5.52	0.0559	ETS2 (directAnnotation).	Malignant cells
	metacluster_174.3	5.33	0.0548	MBD2; NFYA; NFYB; NFYC; PBX3 (directAnnotation).	Malignant cells
	cisbp__M08198	5.16	0.0537	ELF1 (directAnnotation).	Malignant cells
	metacluster_174.2	5.14	0.0536	CEBPZ; CEBPZ; DRAP1; FOS; FOXI1; FOXI1; HMGXB3; IRF3; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYB; NFYB; NFYB; NFYB; NFYB; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; PBX3; PBX3; SP2 (directAnnotation). NFYA; NFYA; NFYC; PBX1; PBX3 (inferredBy_Orthology).	Malignant cells
	taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP	5.04	0.053	ETV5; HOXA2 (directAnnotation).	Malignant cells
	taipale_tf_pairs__ELK1_FOXI1_RSCGGATGTKKN_CAP	5.03	0.0529	ELK1; FOXI1 (directAnnotation).	Malignant cells
	metacluster_197.2	5	0.0527	E2F4; E2F7; E2F7; E2F7; E2F8; E2F8 (directAnnotation).	Malignant cells
	metacluster_34.4	4.88	0.052	ETS1; ETS1; ETS1; HCFC1; SIX5; SIX5; SIX5; SIX5; SMARCC2; SMARCC2; THAP11; THAP11; ZNF143; ZNF143; ZNF143; ZNF143 (directAnnotation). TBX2; THAP11; THAP11; ZNF143 (inferredBy_Orthology).	Malignant cells

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Motifs and TFs regulating down-regulated DEGs in resistant group

motif	motif	NES	AUC	TF_highConf	Cell_type
	hocomoco__TYY2_HUMAN.H11MO.0.D	4.14	0.0889	YY2 (directAnnotation).	Malignant cells
	metacluster_141.6	3.76	0.084	MZF1; TAF1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY2; YY2; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZNF597 (directAnnotation). TAF1; TAF1L (inferredBy_Orthology).	Malignant cells
	metacluster_3.10	3.51	0.0809	KLF2; KLF4 (directAnnotation).	Malignant cells
	taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr	3.45	0.0802	CREB1 (directAnnotation).	Malignant cells
	metacluster_7.5	3.41	0.0797	PLAGL1; PLAGL1 (directAnnotation).	Malignant cells
	metacluster_141.2	3.41	0.0796	E2F2; E2F3 (directAnnotation).	Malignant cells
	metacluster_163.1	3.4	0.0795	KLF1; KLF1; KLF1; KLF1; KLF1; KLF1; KLF1; KLF10; KLF10; KLF12; KLF12; KLF12; KLF13; KLF16; KLF17; KLF2; KLF3; KLF3; KLF3; KLF3; KLF4; KLF4; KLF4; KLF4; KLF4; KLF5; KLF5; KLF5; KLF5; KLF6; KLF6; KLF6; KLF7; KLF9; KLF9; SALL4; SP1; ZNF148; ZNF148; ZNF526 (directAnnotation). EGR4; KLF1; KLF1; KLF12; KLF12; KLF12; KLF13; KLF14; KLF14; KLF14; KLF14; KLF14; KLF14; KLF16; KLF17; KLF17; KLF17; KLF17; KLF17; KLF18; KLF18; KLF18; KLF18; KLF18; KLF18; KLF2; KLF2; KLF3; KLF4; KLF4; KLF4; KLF4; KLF4; KLF4; KLF5; KLF5; KLF5; KLF6; KLF7; KLF7; KLF8; KLF8; KLF9; SP4; SP5; SP5; SP6; SP7; SP8; SP9; ZNF526 (inferredBy_Orthology).	Malignant cells
	transfac_pro__M01783	3.33	0.0786	SP2 (directAnnotation).	Malignant cells
	metacluster_144.8	3.32	0.0784	ZNF30; ZNF30 (directAnnotation).	Malignant cells
	metacluster_155.23	3.31	0.0783	BCL11B; ZNF711; ZNF711 (directAnnotation). ZFY (inferredBy_Orthology).	Malignant cells

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Top

Differentially expressed genes act as transcription factors

This table shows the differentially expressed genes that act as transcription factors. (Complete files can be downloaded from the download section.)

TF	motif	Expression	Cell type	Timepoint
ATF1	metacluster_111.3	up	Malignant cells	NA
ATF1	jaspar__MA0604.1	up	Malignant cells	NA
MTF2	cisbp__M00968	up	Malignant cells	NA
ETS2	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	up	Malignant cells	NA
NFYC	metacluster_174.3	up	Malignant cells	NA
CEBPZ	metacluster_174.2	up	Malignant cells	NA
NFYC	metacluster_174.2	up	Malignant cells	NA
NFYC	metacluster_174.6	up	Malignant cells	NA
ELK3	metacluster_191.3	up	Malignant cells	NA
ETS2	metacluster_191.3	up	Malignant cells	NA

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."